Gastric lavage

bioAffinity Technologies Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, November 14, 2023
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Sale, Lung, BIAF, Acquisition, Research, Exercise, CLIA, CAP, College, CPT, Patient, Clinical Laboratory, LDT, American Medical Association, Marketing, CMS, Lung cancer, Histology, Growth, Medicare, Gastric lavage, DOD, Physician, Military personnel, Observational study, Pharmaceutical industry, Medicaid

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other diseases of the lung, today reported financial results for the three and nine months ended Sept. 30, 2023, and provided a business update.

Key Points: 
  • bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive detection of early-stage lung cancer and other diseases of the lung, today reported financial results for the three and nine months ended Sept. 30, 2023, and provided a business update.
  • CMS is expected to finalize the 2024 payment for CyPath® Lung in November 2023 with an effective date of Jan. 1, 2024.
  • Clinical development expenses were $106,422 for the third quarter of 2023, compared with $60,941 for the third quarter of 2022.
  • Over the next 12 months (fourth quarter 2023 to third quarter 2024), the Company expects to generate between $8.4 and $9.0 million in net revenues.

Arrowhead Presents Data on Pulmonary Pipeline at ERS 2023

Retrieved on: 
Monday, September 11, 2023
Oncology, Health, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Arrowhead, European Respiratory Society, RAGE, Asthma, International, Serum, Gastric lavage, TSLP, Ariad Pharmaceuticals, Inc. v. Eli Lilly & Co., RNA, Lung, ERS, MUC5AC, Arrowhead Pharmaceuticals, Patient, MMP7, BALF, RNA interference, International Congress on Tuberculosis, Safety, Pharmaceutical industry

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced data on its pipeline of pulmonary targeted RNA interference (RNAi) therapeutic candidates, including clinical results for ARO-RAGE, being presented at the European Respiratory Society (ERS) International Congress 2023 in Milan, Italy.

Key Points: 
  • Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced data on its pipeline of pulmonary targeted RNA interference (RNAi) therapeutic candidates, including clinical results for ARO-RAGE, being presented at the European Respiratory Society (ERS) International Congress 2023 in Milan, Italy.
  • Reduction of serum sRAGE was similar in healthy volunteers and in patients with asthma at the 44 mg dose level.
  • Based on interim blinded safety results from the ongoing study, ARO-RAGE has been well-tolerated to date in healthy volunteers and asthma patients.
  • “Today we announced additional data on multiple programs from our emerging pipeline of first-in-class pulmonary targeted RNAi therapeutic candidates at the European Respiratory Society International Congress.

bioAffinity Technologies Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, August 14, 2023
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Exercise, Department of Defense Serum Repository, Medicaid, University, Observational study, CPT, CD320, Marketing, Gastric lavage, Lung cancer, Research, BIAF, RNA, Lung, Military personnel, Small RNA, American Medical Association, Medicare, DOD, Congress, COVID-19, Patient, Physician, Flow cytometry, AMA, CFO, City, LRP2, Therapy, International Society, Pharmaceutical industry

Revenue for the second quarter of 2023 was $20,000, compared with $1,000 for the prior-year period.

Key Points: 
  • Revenue for the second quarter of 2023 was $20,000, compared with $1,000 for the prior-year period.
  • Research and development expenses were $335,000 for the second quarter of 2023, compared with $248,000 for the comparable period in 2022.
  • Clinical development expenses were $35,000 for the second quarter of 2023, compared with $28,000 for the second quarter of 2022.
  • Selling, general and administrative expenses were $1.4 million for the second quarter of 2023, compared with $409,000 for the comparable period in 2022.

Revolo Biotherapeutics Presents New Preclinical Data for ‘1104 in Acute Respiratory Distress Syndrome Associated With Influenza Infection at the ATS 2023 International Conference

Retrieved on: 
Monday, May 22, 2023
IAV, Infection, Mouse, MOA, Eosinophilic esophagitis, TNF, Neutrophil, Allergy, Macrophage, Gastric lavage, ATS, Influenza A virus, IL-6, Inflammation, American Thoracic Society, Lung, Dexamethasone, Animal, International Conference on Emerging Infectious Diseases, Organic acid, Patient, Immune system, Viral, Viral load, Acute respiratory distress syndrome, Chemokine, Cytokine, Lymphocyte, Immunosuppression, Conference, PBS, Autoimmunity, Disease, Vaccine, Revolo

NEW ORLEANS and CAMBRIDGE, UK,, May 22, 2023 (GLOBE NEWSWIRE) -- Revolo Biotherapeutics (“Revolo” or the “Company”), a company developing therapies that reset the immune system to achieve superior long-term remission for patients with autoimmune and allergic diseases, today announced new preclinical data discussed in a poster presentation at the American Thoracic Society (ATS) 2023 International Conference. The poster showcases the ability of its immune-resetting drug candidate ‘1104 to inhibit and reduce lung inflammation without immunosuppression in a new model of acute respiratory distress syndrome (ARDS) associated with influenza infection.

Key Points: 
  • The poster showcases the ability of its immune-resetting drug candidate ‘1104 to inhibit and reduce lung inflammation without immunosuppression in a new model of acute respiratory distress syndrome (ARDS) associated with influenza infection.
  • “The data continues to highlight the unique mechanism of action (MOA) of ‘1104, acting ahead of the inflammatory cascade to reset the immune system.
  • Three days after infection, animals received either PBS (negative control) or 30µg of polyinosinic-polycytidylic acid (poly I:C) to exacerbate influenza-induced lung inflammation.
  • At 48 hours after the poly I:C challenge, bronchoalveolar lavage fluid was collected to conduct differential cell counts and to measure cytokines.

Inhibrx Announces Opportunity for Accelerated Approval Pathway on Functional AAT Serum Levels for INBRX-101 in AATD and Announces Bronchoalveolar Lavage Fluid Detection Results from the Phase 1 Study

Retrieved on: 
Tuesday, October 4, 2022
Degenerative disease, Neutralizing antibody, U.S. Securities and Exchange Commission, Lung, Drug development, SEC, Serum, Technology, Risk, Collection, Nasdaq, Research, Gastric lavage, Private Securities Litigation Reform Act, Food, Protein engineering, Bristol Myers Squibb, AAT, FDA, Respiratory disease, COVID-19, Annual report, Webcast, Sumathi Best Television Current Reporting Award, Safety, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, SAN, Plasma, Patient, MM, Life expectancy, BALF, Therapy, Company, Pharmaceutical industry, Vaccine, AATD, Chiesi Farmaceutici

Inhibrx also announced the detection of INBRX-101 in the bronchoalveolar lavage fluid (BALF) samples from all AATD patients tested in the Phase 1 study.

Key Points: 
  • Inhibrx also announced the detection of INBRX-101 in the bronchoalveolar lavage fluid (BALF) samples from all AATD patients tested in the Phase 1 study.
  • The FDA expressed support to collaborate and work with Inhibrx to address the regulatory challenges associated with AATD drug development.
  • The FDA also requested additional data on the correlation between functional AAT levels and the clinical benefit in AATD to further support serum AAT levels as a surrogate endpoint that is reasonably likely to predict clinical benefit, the prerequisite for accelerated approval.
  • The accelerated approval pathway can be used for a drug intended for a serious or life-threatening illness that provides a meaningful therapeutic advantage over existing treatments.

Apricot Snacks Poison Rural Canadian Puppy

Retrieved on: 
Wednesday, August 17, 2022
Death, Vomiting, Instinct, GiFT, Veterinarian, Melissa, Cat, Golden Retriever, Hydrogen peroxide, Arrhythmia, Dog, Poisoning, Medicine, Pharmacy, Gastric lavage, Plant, Life, PETS, Seed, Human, Obstruction, Cell, Bird, Toxicology, Shock, Panic, GPS, Ataxia, Blood pressure, Seizure, Antidote, Head, Animal, Veterinary medicine, Golden, Subaru, COVID-19

MINNEAPOLIS, Aug. 17, 2022 /PRNewswire/ -- Sometimes, it is just good to be lucky. When Melissa Martin decided to take her Golden Retriever puppy Subaru with her on a trip to the "big city," she had no idea it would save the dog's life. Martin breeds Golden Retrievers at her home in Dobbinton, Ontario, Canada, which is a three-hour drive from Toronto. While delivering one of her new puppies to its forever home, Martin decided to take Subaru along for the ride.

Key Points: 
  • "I was dropping off a puppy in Toronto, and left Subaru in the front seat of the vehicle.
  • When I came back from delivering the puppy, I found that Subaru had dug out a 300-count bag of apricot kernels I keep in the console."
  • While many people enjoy eating apricot kernels, which are the seeds found inside the hard pit, they can be dangerous to pets.
  • As the most cost-effective option for animal poison control care, Pet Poison Helpline's fee of $75 per incident includes follow-up consultations for the duration of the case.

Pliant Therapeutics Highlights Recent Developments for Lead Program PLN-74809 and Expected 2022 Milestones

Retrieved on: 
Tuesday, January 11, 2022
Vital capacity, Webcast, Patient, Fatty liver disease, News, Conference, SAN, Conversation, LinkedIn, Financial condition report, Private Securities Litigation Reform Act, SEC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, COVID-19, Primary sclerosing cholangitis, Partnership, Safety, Risk, Cirrhosis, CEO, Integrin, GLOBE, Muscular dystrophy, NASH, Nasdaq, Facebook, PSC, Therapy, BAL, Program, Pharmacokinetics, YouTube, Result, IPF, Gastric lavage, Fibrosis, Food, Annual report, Twitter, Idiopathic pulmonary fibrosis, FDA, FVC, QLF, Event, Orphan, Analysis, Pharmaceutical industry, Novartis, Company

SOUTH SAN FRANCISCO, Calif., Jan. 11, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis, today provided an update on its PLN-74809 program. The Company will present these updates at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022, at 9:45 a.m. ET/ 6:45 a.m. PT.

Key Points: 
  • Furthermore, this illustrates another step in the ongoing de-risking of PLN-74809 in IPF and positions the program for later stage development.
  • In December, the Company completed enrollment of its INTEGRIS-IPF Phase 2a clinical trial in patients with idiopathic pulmonary fibrosis (IPF).
  • Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis.
  • Pliant is currently recruiting Phase 2a trials of PLN-74809 in the lead indications of IPF and PSC.

BrainStorm Announces Scientific Presentation of NurOwn® Exosome Preclinical ARDS Data at NYSCF 2021 VIRTUAL Meeting

Retrieved on: 
Monday, October 18, 2021
Gastric lavage, EMA, Exo, Cell, Microsoft, NTFS, LPS, Sev Ohanian, Amphiregulin, California Institute for Regenerative Medicine, Respiratory disease, European Medicines Agency, Poster, National, CIRM, Mortality, Therapy, MS, HGF, FDA, Exosome, Multiple sclerosis, Orphan drug, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Neurodegeneration, Food, Phrase, Hepatocyte growth factor, Amyotrophic lateral sclerosis, Company, MSC, Annual report, Brainstorm, California, LIF, AREG, Regenerative medicine, Safety, NASDAQ, Leukemia inhibitory factor, Research, BALF, TSG-6, Pharmaceutical industry, Medical imaging, Vaccine

The NurOwntechnology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders.

Key Points: 
  • The NurOwntechnology platform (autologous MSC-NTF cells) represents a promising investigational therapeutic approach to targeting disease pathways important in neurodegenerative disorders.
  • MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo.
  • About BrainStorm Cell Therapeutics Inc.
    BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.
  • Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.